Form 4: Actuate Therapeutics Director Todd Thomson Granted 15,000 Stock Options

Actuate Therapeutics, Inc. disclosed that Director and 10% Owner Todd S. Thomson was granted 15,000 stock options with an exercise price of $10.1, vesting fully on the anniversary of the grant date.

Summary

• Todd S. Thomson, a Director and 10% Owner of Actuate Therapeutics, Inc. (ACTU), was granted 15,000 stock options.
• The options have an exercise price of $10.1 per share.
• The grant date for these options was May 22, 2025, and they expire on May 22, 2035.
• The options are set to vest in full on the anniversary of the grant date (May 22, 2026).
• Mr. Thomson holds these options directly, and they represent an indirect pecuniary interest for certain funds managed by Kairos Venture Investments, LLC, where Mr. Thomson serves as CFO/COO and board representative.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director, which is a neutral event but can be seen as a positive for aligning interests. There are no negative financial disclosures or red flags. The slight positive sentiment comes from the alignment of interests and the long-term incentive provided.

Positives

• Grant of stock options to a director and significant owner aligns management's interests with shareholder value.
• The options have a 10-year expiration period, providing a long-term incentive.

Negatives

• No immediate negative financial implications are apparent from a routine stock option grant.

Risks

• The value of the stock options is dependent on the future stock price of Actuate Therapeutics, Inc. exceeding the exercise price of $10.1.

Future Outlook

The grant of stock options provides a long-term incentive for the director, aligning their future financial interests with the company's stock performance over the next decade.

Management Comments

• "Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ('KVI'), and serves on the board of directors (the 'Board') of Actuate Therapeutics, Inc. ('Actuate')."
• "Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the 'Kairos Funds') and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4."

Industry Context

This Form 4 filing is a routine disclosure of an equity grant to a director, common practice across industries to incentivize leadership and align their interests with long-term company performance. The involvement of Kairos Venture Investments, LLC suggests a venture capital or institutional investor's representation on the board, typical for companies in growth or development phases, particularly in the therapeutics sector.

Comparison to Industry Standards

• The grant of 15,000 stock options to a director and 10% owner is a standard form of equity compensation.
• The exercise price of $10.1 and a 10-year expiration period are within typical ranges for such grants in the biotechnology and pharmaceutical industries, where long-term incentives are crucial given the extended development cycles of therapeutic products.
• Specific comparable companies or projects are not detailed in this filing, but similar grants are observed across small to mid-cap biotech firms like those developing novel therapies.

Related Party Transactions

• The grant of stock options to Todd S. Thomson, a Director and 10% Owner, constitutes a related party transaction.
• Mr. Thomson's role as a representative of Kairos Funds on the board means that Kairos Funds have an indirect pecuniary interest in these securities.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the options gain value only if the stock price increases. However, it also represents potential future dilution upon exercise.
• Management/Employees: Reinforces the company's compensation structure for key personnel and board members.

Next Steps

• The stock options will vest in full on May 22, 2026.
• Todd S. Thomson may exercise the vested options at any time before the expiration date of May 22, 2035.

Key Dates

Keywords

Actuate Therapeutics, ACTU, Todd Thomson, Stock Options, SEC Form 4, Insider Trading, Beneficial Ownership, Director Compensation, Equity Grant, Kairos Venture Investments